Progress in developing cationic vectors for non-viral systemic gene therapy against cancer
Source abstract
Abstract
Initially, gene therapy was viewed as an approach for treating hereditary diseases, but its potential role in the treatment of acquired diseases such as cancer is now widely recognized. The understanding of the molecular mechanisms involved in cancer and the development of nucleic acid delivery systems are two concepts that have led to this development. Systemic gene delivery systems are needed for therapeutic application to cells inaccessible by percutaneous injection and for multi-located tumor sites, i.e. metastases. Non-viral vectors based on the use of cationic lipids or polymers appear to have promising potential, given the problems of safety encountered with viral vectors. Using these non-viral vectors, the current challenge is to obtain a similarly effective transfection to viral ones. Based on the advantages and disadvantages of existing vectors and on the hurdles encountered with these carriers, the aim of this review is to describe the "perfect vector" for systemic gene therapy against cancer.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Virus-based gene therapy research · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Somatic alterations in the human cancer genome10.1016/j.ccr.2004.11.004 ↗
2. Gene therapy for cystic fibrosis airway disease – is clinical success imminent?10.2174/156652306776359496 ↗
3. Gene therapy clinical trials worldwide 1989–2004 – an overview10.1002/jgm.619 ↗
4. Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model
5. Stability analysis for long-term storage of naked DNA: impact on nonviral in vivo gene transfer10.1016/S0003-2697(03)00244-6 ↗
6. Chitosan–DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy10.1016/S0939-6411(03)00155-3 ↗
7. An overview of current delivery systems in cancer gene therapy10.1016/j.jconrel.2003.09.013 ↗
8. Retroviruses10.1126/science.3287617 ↗
9. Expression and localization of human papillomavirus type 16 E6 and E7 open reading frame proteins in human epidermal keratinocyte10.3349/ymj.1994.35.1.1 ↗
10. Use of adeno-associated virus as a general transduction vector for mammalian cells
11. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency10.1093/nar/27.19.3792 ↗
12. Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan–DNA nanoparticles10.1016/S0142-9612(02)00507-0 ↗
13. Targeting tumors with non-viral gene delivery systems10.1016/S1359-6446(02)02243-2 ↗
14. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery10.1038/sj.gt.3302838 ↗
15. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer10.1016/S0169-409X(02)00046-7 ↗
16. Non-viral vectors in cancer gene therapy: principles and progress10.1097/00001813-200104000-00001 ↗
17. Aerosol gene delivery in vivo10.1073/pnas.89.23.11277 ↗
18. Block and graft copolymers and NanoGel copolymer networks for DNA delivery into cell10.3109/10611860008996855 ↗
19. Cellular and molecular neurosurgery: pathways from concept to reality, part II: vector systems and delivery methodologies for gene therapy of the central nervous system10.1097/00006123-199704000-00028 ↗
20. PEGylated DNA/transferrin–PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery10.1038/sj.gt.3300900 ↗
21. Gene delivery with low molecular weight linear polyethylenimines10.1002/jgm.775 ↗
22. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine10.1073/pnas.92.16.7297 ↗
23. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity10.1023/A:1014861900478 ↗
24. Efficient gene transfer using reversibly cross-linked low molecular weight polyethylenimine10.1021/bc0100455 ↗
25. Polyelectrolyte vectors for gene delivery: influence of cationic polymer on biophysical properties of complexes formed with DNA10.1021/bc990025r ↗
26. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system10.1016/S0021-9258(18)61209-8 ↗
27. Stabilization of poly-l-lysine/DNA polyplexes for in vivo gene delivery to the liver10.1016/S0167-4781(98)00274-7 ↗
28. Systemic circulation of poly(l-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy10.1182/blood.V97.8.2221 ↗
29. Biodegradable polyester, poly[alpha-(4-aminobutyl)-l-glycolic acid], as a non-toxic gene carrier10.1023/A:1007552007765 ↗
30. Degradable polymeric carrier for the delivery of IL-10 plasmid DNA to prevent autoimmune insulitis of NOD mice10.1038/sj.gt.3301334 ↗
31. Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice10.1006/mthe.2001.0459 ↗
32. Immersion delivery of plasmid DNA. II. A study of the potentials of a chitosan based delivery system in rainbow trout (Oncorhynchus mykiss) fry10.1016/S0168-3659(02)00278-X ↗
33. Chitosan-based gastrointestinal delivery systems10.1016/S0168-3659(03)00126-3 ↗
34. Chitosan as a novel nasal delivery system for vaccines10.1016/S0169-409X(01)00171-5 ↗
35. Interactions of phospholipid bilayer with chitosan: effect of molecular weight and pH10.1021/bm015548s ↗
36. Chitosan as a nonviral gene delivery system: structure–property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo10.1038/sj.gt.3301492 ↗
37. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability10.1023/A:1011981000671 ↗
38. Galactosylated chitosan (GC)-graft-poly(vinyl pyrrolidone) (PVP) as hepatocyte-targeting DNA carrier: in vitro transfection10.1007/BF02975895 ↗
39. Quaternized chitosan oligomers as novel gene delivery vectors in epithelial cell lines10.1016/S0142-9612(01)00090-4 ↗
40. Preparation of oxidized glucose-crosslinked N-alkylated chitosan membrane and in vitro studies of pH-sensitive drug delivery behaviour10.1016/S0142-9612(01)00111-9 ↗
41. Structural characteristics of size-controlled self-aggregates of deoxycholic acid-modified chitosan and their application as a DNA delivery carrier10.1021/bc015510c ↗
42. In vitro gene delivery mediated by chitosan: effect of pH, serum, and molecular mass of chitosan on the transfection efficiency10.1016/S0142-9612(00)00385-9 ↗
43. Development and characterisation of chitosan nanoparticles for siRNA delivery10.1016/j.jconrel.2006.07.021 ↗
44. Supramolecular solubilisation of hydrophilic dyes by using individual dendritic branches10.1002/1521-3765(20011105)7:21<4730::AID-CHEM4730>3.0.CO;2-A ↗
45. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers10.1093/nar/24.11.2176 ↗
46. Gene transfer into eukaryotic cells using activated polyamidoamine dendrimers
47. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity10.1038/sj.gt.3302579 ↗
48. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers10.1073/pnas.93.10.4897 ↗
49. In vitro gene delivery by degraded polyamidoamine dendrimers10.1021/bc9600630 ↗
50. The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes10.1038/sj.gt.3300454 ↗
51. [In vivo expression of green fluorescent protein gene and immunogenicity of ES312 vaccine both mediated by starburst polyamidoamine dendrimers]
52. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure10.1073/pnas.84.21.7413 ↗
53. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations10.1016/S0021-9258(17)41980-6 ↗
54. Combinatorial synthesis of new cationic lipids and high-throughput screening of their transfection properties10.1002/1439-7633(20020902)3:9<852::AID-CBIC852>3.0.CO;2-A ↗
55. Structure of DNA–cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes10.1126/science.275.5301.810 ↗
56. An inverted hexagonal phase of cationic liposome–DNA complexes related to DNA release and delivery10.1126/science.281.5373.78 ↗
57. Phase behavior, DNA ordering, and size instability of cationic lipoplexes: relevance to optimal transfection activity10.1074/jbc.M105588200 ↗
58. Lipoplex formation under equilibrium conditions reveals a three-step mechanism10.1016/S0006-3495(00)76396-X ↗
59. Cationic lipid–DNA complexes–lipoplexes for gene transfer and therapy10.1016/S1567-5394(02)00132-9 ↗
60. Cationic liposome-mediated gene transfer
61. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery10.1089/hum.1996.7.12-1437 ↗
62. Systemic gene expression after intravenous DNA delivery into adult mice10.1126/science.7687073 ↗
63. Immunostimulatory activity of cationic-lipid–nucleic-acid complexes against cancer10.1007/s00432-001-0318-x ↗
64. In vivo gene transfer via intravenous administration of cationic lipid–protamine–DNA (LPD) complexes10.1038/sj.gt.3300482 ↗
65. Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration10.1038/sj.gt.3300424 ↗
66. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery10.1038/nbt0297-167 ↗
67. Cationic lipid-based gene delivery systems: pharmaceutical perspectives10.1023/A:1012187414126 ↗
68. A novel series of amphiphilic imidazolinium compounds for in vitro and in vivo gene delivery10.1021/bi00041a033 ↗
69. Improved DNA: liposome complexes for increased systemic delivery and gene expression10.1038/nbt0797-647 ↗
70. Interaction between DNA–cationic liposome complexes and erythrocytes is an important factor in systemic gene transfer via the intravenous route in mice: the role of the neutral helper lipid10.1038/sj.gt.3301460 ↗
71. Systemic gene therapy: biodistribution and long-term expression of a transgene in mice10.1073/pnas.92.21.9742 ↗
72. Biodistribution and gene expression of lipid/plasmid complexes after systemic administration10.1089/hum.1998.9.14-2083 ↗
73. In vivo gene transfer by intravenous administration of stable cationic lipid/DNA complex10.1023/A:1012146305040 ↗
74. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors
75. CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo10.1006/mthe.2002.0598 ↗
76. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector10.1006/mthe.2001.0266 ↗
77. Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations10.1080/08982100500528685 ↗
78. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo10.1038/sj.cgt.7700793 ↗
79. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs10.1038/nbt1122 ↗
80. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery10.1089/hum.2006.17.117 ↗
81. Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer10.1038/sj.cgt.7700753 ↗
82. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer10.1158/1078-0432.CCR-04-1049 ↗
83. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery10.1158/0008-5472.CAN-05-0530 ↗
84. Phase I study of liposome–DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases10.1089/hum.2005.16.937 ↗
85. Towards synthetic viruses10.1016/S0169-409X(01)00213-7 ↗
86. Synthetic DNA delivery systems10.1038/71889 ↗
87. Jet nebulization of PEI/DNA polyplexes: physical stability and in vitro gene delivery efficiency10.1002/jgm.225 ↗
88. Cloning of cDNA from induced K562 cells which can activate globin gene expression
89. Protamine sulfate enhances lipid-mediated gene transfer10.1038/sj.gt.3300484 ↗
90. Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated gene transfer in vitro and in vivo10.1038/sj.gt.3300795 ↗
91. An SV40 large T antigen binding site in the cellular genome is part of a cis-acting transcriptional element
92. In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density10.1016/S0168-3659(00)00358-8 ↗
93. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo10.1002/(SICI)1521-2254(199903/04)1:2<111::AID-JGM22>3.0.CO;2-Y ↗
94. Nanoparticles in cancer therapy and diagnosis10.1016/S0169-409X(02)00044-3 ↗
95. Complement activation by injectable colloidal drug carriers
96. Molecular organization and function of the complement system10.1146/annurev.bi.57.070188.001541 ↗
97. Biodegradable long-circulating polymeric nanospheres10.1126/science.8128245 ↗
98. Parameters influencing the stealthiness of colloidal drug delivery systems10.1016/j.biomaterials.2006.03.039 ↗
99. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells10.1016/S0005-2760(97)00169-0 ↗
100. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 310.1038/35099560 ↗